^
    Apply
    Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab (MAVRiC) (NCT07024706)
    Phase 2
    AstraZeneca
    Not yet recruiting
    Last update posted :
    06/17/2025
    Initiation :
    09/30/2025
    Primary completion :
    11/30/2032
    Completion :
    11/30/2032
    BCL2
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03516617)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/10/2018
    Primary completion :
    03/15/2030
    Completion :
    03/15/2031
    CD20 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (19-C-0116) (NCT04002947)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2026
    Completion :
    03/31/2030
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL (ASCEND) (NCT02970318)
    Phase 3
    Acerta Pharma BV
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/02/2017
    Primary completion :
    09/03/2021
    Completion :
    10/01/2027
    CD5 • FCER2
    |
    CD20 positive
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • Zydelig (idelalisib) • bendamustine
    Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) (NCT04008706)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/17/2019
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    TP53 • CD20 • IGH • CD5 • FCER2
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma (NCT05495464)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    11/18/2022
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5
    |
    CD20 positive • Chr t(11;14)
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04169737)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/29/2020
    Primary completion :
    07/09/2026
    Completion :
    07/09/2026
    TP53 • IGH
    |
    TP53 mutation • Chr del(11q)
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL (15-H-0016) (NCT02337829)
    Phase 2
    Acerta Pharma BV
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    01/12/2015
    Primary completion :
    06/26/2020
    Completion :
    04/01/2026
    TP53
    |
    TP53 mutation
    |
    Calquence (acalabrutinib)
    Avo In R/R And Previously Untreated MCL (NCT04855695)
    Phase 1/2
    Austin I Kim
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    07/02/2021
    Primary completion :
    12/31/2025
    Completion :
    06/01/2026
    TP53
    |
    TP53 wild-type
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (ACALLO) (NCT04716075)
    Phase 2
    Polish Lymphoma Research Group
    Completed
    Last update posted :
    01/16/2025
    Initiation :
    08/19/2019
    Primary completion :
    06/30/2024
    Completion :
    07/30/2024
    TP53
    |
    TP53 mutation
    |
    Calquence (acalabrutinib)
    A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients with High Risk CLL (CLL16) (NCT05197192)
    Phase 3
    German CLL Study Group
    Recruiting
    Last update posted :
    12/30/2024
    Initiation :
    04/19/2022
    Primary completion :
    05/01/2028
    Completion :
    05/01/2028
    TP53 • BCL2
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma (NCT05256641)
    Phase 1/2
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    11/05/2024
    Initiation :
    01/23/2023
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BCL2 • BCL6
    |
    Calquence (acalabrutinib)